Valuation : Geron Corporation

Market Cap 1.02B 879M 825M 755M 1.41B 96.57B 1.42B 9.76B 3.8B 49.35B 3.84B 3.75B 159B P/E 2026 *
-37.9x
P/E 2027 * 23.4x
Enterprise Value 1.02B 879M 825M 755M 1.41B 96.57B 1.42B 9.76B 3.8B 49.35B 3.84B 3.75B 159B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 2.99x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-5.35%
1 week-1.63%
Current month+1.01%
1 month+17.58%
3 months+29.74%
6 months+4.51%
Current year+14.02%
1 week 1.45
Extreme 1.45
1.62
1 month 1.31
Extreme 1.31
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-5.35%-1.63%+7.50%-38.32% 1.02B
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.06%+4.02%-12.01%+378.84% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.97%-7.68%+2.41%-15.70% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.06%+6.88%+59.79%+165.20% 14.5B
Average +0.49%-2.00%+44.07%+161.17% 28.14B
Weighted average by Cap. +1.06%-2.10%+42.84%+141.39%

Financials

2026 *2027 *
Net sales 236M 203M 191M 175M 326M 22.34B 328M 2.26B 879M 11.41B 887M 868M 36.76B 342M 294M 276M 253M 471M 32.33B 475M 3.27B 1.27B 16.52B 1.28B 1.26B 53.2B
Net income -27.18M -23.39M -21.95M -20.08M -37.48M -2.57B -37.77M -260M -101M -1.31B -102M -99.84M -4.23B 50.14M 43.14M 40.49M 37.04M 69.14M 4.74B 69.68M 479M 187M 2.42B 188M 184M 7.8B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-09-03 $1.500 -5.66% 12,326,942
26-09-02 $1.590 +7.43% 26,890,023
26-09-01 $1.480 -0.67% 7,886,442
26-08-31 $1.490 -1.32% 7,247,301
26-08-28 $1.510 -1.31% 7,416,982
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.590USD
Average target price
4.250USD
Spread / Average Target
+167.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock